Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Barclays

Equities researchers at Barclays assumed coverage on shares of Enliven Therapeutics (NASDAQ:ELVN) in a note issued to investors on Tuesday,Benzinga reports. The brokerage set an “overweight” rating and a $78.00 price target on the stock. Barclays‘s price target would indicate a potential upside of 31.03% from the stock’s current price.

A number of other research analysts have also recently issued reports on ELVN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Friday, July 17th. Wall Street Zen lowered Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. JonesTrading increased their target price on Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a report on Monday, June 29th. Guggenheim reduced their price target on Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Finally, HC Wainwright lifted their price target on Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, July 9th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $75.00.

Enliven Therapeutics Stock Performance

Shares of Enliven Therapeutics stock opened at $59.53 on Tuesday. Enliven Therapeutics has a 52-week low of $14.78 and a 52-week high of $62.32. The company has a fifty day moving average of $51.42 and a 200-day moving average of $41.13. The stock has a market capitalization of $4.36 billion, a price-to-earnings ratio of -35.65 and a beta of 0.27.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). On average, equities research analysts forecast that Enliven Therapeutics will post -1.67 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction dated Friday, July 17th. The shares were sold at an average price of $52.64, for a total transaction of $316,787.52. Following the completion of the sale, the chief financial officer directly owned 46,054 shares in the company, valued at approximately $2,424,282.56. This represents a 11.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $34.54, for a total value of $345,400.00. Following the completion of the sale, the director directly owned 51,884 shares in the company, valued at $1,792,073.36. The trade was a 16.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 190,831 shares of company stock valued at $10,991,723. Insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

A number of large investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Enliven Therapeutics by 8.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock valued at $428,000 after acquiring an additional 1,693 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Enliven Therapeutics by 61.3% in the first quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company’s stock valued at $4,167,000 after acquiring an additional 80,506 shares in the last quarter. Jane Street Group LLC bought a new stake in Enliven Therapeutics in the first quarter valued at $578,000. Legal & General Group Plc increased its position in Enliven Therapeutics by 52.2% during the 2nd quarter. Legal & General Group Plc now owns 32,225 shares of the company’s stock valued at $646,000 after purchasing an additional 11,058 shares during the period. Finally, Quantbot Technologies LP raised its holdings in Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after purchasing an additional 1,434 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.